Page 1,722«..1020..1,7211,7221,7231,724..1,7301,740..»

The gut microbiome-metabolome dataset collection: a curated resource for integrative meta-analysis | npj Biofilms and Microbiomes – Nature.com

The data resource includes curated and unified data tables from 14 different human gut (feces) microbiome-metabolome published studies from recent years (Table 1, Supplementary Table 1)8,9,10,13,14,15,16,17,18,19,20,21,22,23. Figure 1a highlights the main data sources and key processing steps. For each study we provide 4 processed tables: A genus-level abundance table, a metabolite abundance table, a metabolite identifiers mapping table, and a sample metadata table including sample- and subject-characteristics (Fig. 1b). For studies with shotgun metagenomics we also provided species-level abundance tables. Importantly, microbiome profiles were obtained through processing of raw metagenomics sequencing data, while for metabolite profiles we obtained already processed tables due to the substantial differences between metabolomics instruments and approaches. Where possible, both taxa and metabolite identifiers have been unified, allowing comparison across studies (see Methods). The data for each study are provided both as simple text files (.tsv) and as R-data files (.RData), and are accessible via a public GitHub repository. We further provide detailed documentation and a usage example in a dedicated Wiki page and via script examples also available in the repository. New datasets could be added to the resource by Git pull requests, following the instructions provided in the Wiki section Adding new datasets. Overall, 2900 samples from 1849 individuals are currently included in the resource (Fig. 1c). Most of these studies are case-control studies, i.e. they include two study groups, one consisting of individuals with a specific medical condition, and another group of healthy control individuals (Table 1).

a A highlight of data resources and main processing steps of the curated microbiome-metabolome data resource (see Methods); b A database scheme of the final data products per dataset. Each box describes a specific table and its content and primary key (PK) field. The species table is only available for studies with shotgun metagenomic data; c Data resource summary statistics; d Genera prevalence across datasets. Each bar represents the number of unique genera that appear in at least the specified number of datasets; e Metabolite prevalence across datasets, interpretation equivalent to (d).

The described resource, which includes hundreds of unique metabolites and thousands of unique genera that appear in multiple independent datasets (Fig. 1d, e), could be used for different types of meta-analyses or cross-study comparisons involving paired microbiome and metabolome data across health and disease. We specifically identify 3 main categories of analysis use cases, facilitated by this resource: First, this resource can be used for meta-analysis efforts where associations of different types are compared across some or all datasets, aiming to identify robust and consistent signals. Such associations could be identified via a wide range of statistical methods, univariate or multivariate approaches, and using a wide range of features, e.g. taxa at different ranks, microbiome diversity metrics, sample or subject characteristics, metabolite features, etc. Two examples of such meta-analysis efforts are further described below. Second, this resource can be used to benchmark methods related to the joint analysis of microbiome and metabolome data. For example, machine learning methods for predicting metabolite levels based on taxonomic features have been recently proposed but validated on only a very small set of datasets24,25. Third, researchers analyzing new microbiome-metabolome datasets can use this resource to add support for findings on their own data, using specific datasets from the resource that resemble their own cohort (studies on the same disease, for example, or using an identical metabolomics method).

Indeed, we recently demonstrated the utility of a similar dataset collection in a large-scale meta-analysis of the relationship between gut microbes and metabolites26. In this study we were interested in pinpointing metabolites that are robustly and universally predicted by the microbiotas composition in a healthy population across multiple studies. Using a combination of random forest regressor models (for predicting metabolites) and random-effects models (for quantifying robustness), we were able to identify 97 metabolites that were robustly well-predicted by the microbiotas composition. We additionally found that multiple microbiome-metabolite relationships are study-specific, implying that links based on a single study should be interpreted with caution and highlighting the importance of validating findings on additional data sources.

Here, as an additional use-case example, we present another meta-analysis of the microbiome-metabolome relationship, searching for specific genus-metabolite associations that are significant and consistent across multiple datasets (see Methods). For this analysis we included only the 11 non-infant cohorts from our resource, and analyzed a total of 29,708 unique genus-metabolite pairs that appeared in at least 3 different datasets. These pairs included 109 different GTDB genera and 314 metabolites. We used linear models to estimate the association between a specific genuss abundance and a specific metabolites level, while controlling for disease state (i.e. study group). Overall, 132,391 linear models were fitted, of which, 18,075 (13.6%) resulted in a significant genus-metabolite association (i.e. regression coefficient FDR 0.05). Comparing the associations direction and significance across datasets, we found multiple genus-metabolite pairs associated in some (and often, all) datasets, but interestingly also pairs with conflicting associations in different datasets (Fig. 2a). Notably, genus-metabolite correlations can clearly stem from a direct involvement of the genus in the production, consumption, or degradation of the metabolite, but also from indirect associations related, for example, to interactions between different gut bacteria, or co-abundant metabolites present in specific diets. We similarly emphasize that the analyzed metabolites can be either endogenous to the host, obtained through diet, microbially produced/transformed, or otherwise acquired from the environment. Finding associations across multiple datasets, as facilitated by our resource, potentially increases the likelihood that such associations are microbially driven and represent ubiquitous microbial metabolism, rather than specific host or diet-related associations.

a Associations between genera and metabolites were tested using linear models, in each dataset independently and controlling for study groups. The dot plot illustrates association results for the top 70 associated metabolites and the top 40 associated genera. Each dot represents a genus-metabolite pair, dot size represents the number of datasets in which the pair was analyzed, and dot colors represent the percent of datasets in which a significant association (positive or negative) was found (see also Methods). A question mark indicates conflicting results between 2 or more datasets, i.e. at least one significant negative association and at least one significant positive association. Metabolites (grid columns) are grouped by their metabolite classes, abbreviated as follows: Ben. Benzenoids, OS Other steroids, Cbxm. Carboximidic acids, COOH Carboxylic acids and derivatives, AA Amino acids, OO Other organic acids, ONC Organonitrogen compounds, CHO Carbohydrates and carbohydrate conjugates, OHC Organoheterocyclic compounds, PPA Phenylpropanoic acids. Genera (grid rows) are grouped by their order taxonomic rank, abbreviated as follows: Actin. Actinomycetales (Actinobacteriota phylum), Bacte. Bacteroidales (Bacteroidota phylum), Lachn. Lachnospirales (Firmicutes_A phylum), Oscil. Oscillospirales (Firmicutes_A phylum), Chris. Christensenellales (Firmicutes_A phylum), Veill. Veillonellales (Firmicutes_C phylum), Enter. Enterobacterales (Proteobacteria phylum), b A bipartite network of consistent genus-metabolite associations, identified by a meta-analysis of 11 different microbiome-metabolome datasets from the curated microbiome-metabolome data resource. Green nodes represent genera, with node sizes proportional to genus average relative abundance, and orange nodes represent metabolites. Edges between genus nodes and metabolite nodes represent a consistent positive (blue) or negative (red) association. Details about the network nodes and edges are available in Supplementary Table 4.

Moreover, to determine which genus-metabolite pairs are consistently associated in a more statistically rigorous manner, we conducted a random-effects meta-analysis using semi-partial correlations derived from the linear regression results (as suggested by Aloe and Becker, 201227). We identified 1101 consistent associations, including in total 104 genera and 195 metabolites (Fig. 2b, Supplementary Table 4; see Methods). Metabolite-associated genera were mostly from the Firmicutes_A phylum but included other phyla as well. Microbe-associated metabolites spanned multiple metabolite classes, with the organic nitrogen compounds super-class being enriched for microbially-associated metabolites (odds ratio 3.47 [1.3, ], FDR 0.08), and the organic acids and derivatives super-class being specifically enriched for Bacteroidota-associated metabolites (odds ratio 3.21 [2, ], FDR 0.0004; see Methods).

We additionally examined the bipartite network of consistently associated genera and metabolites, presented in Fig. 2b. A full list of network edges, alongside meta-analysis results, are provided in Supplementary Table 4. We identified several genera with a particularly high number of metabolite associations, including ER4 and Dysosmobacter (both of which were previously identified as Oscillibacter genus), Alistipes, and the recently re-classified Alistipes_A genus (Fig. 2b-I). Even though most of these genera have a relatively low abundance in the human gut (0.36%, 0.66%, 3.3% and 0.1%, respectively, averaged over all samples and datasets in the analysis), they are connected to the highest number of metabolites in the network (51, 44, 43 and 50, respectively). This observation may be explained by at least two potential hypotheses: (i) that these bacteria are highly metabolically active in the gut, and/or (ii) that they possess central ecological roles in the gut microbial ecosystem. The former hypothesis is supported, for example, by a recent study on the newly isolated human commensal Dysosmobacter welbionis, where administration of this species to mice was found to strongly influence host metabolism and counteract diet-induced obesity development, with only negligible impact on the overall microbiota composition28. Alistipes commensal species are also well-studied for their diverse metabolic functions in the gut29. Another recent study, however, supported the latter hypothesis when reporting that based on a gut microbiome analysis of a large Dutch cohort, several Alistipes, Alistipes_A, and unclassified Oscillibacter species were all identified as keystone species, predicted to have an important impact on the entire microbiome structure and function30. Lastly, we note that analogously to highly-associated genera, there are also a few metabolites that are associated with a high number of genera (over 30). This is perhaps not surprising as some metabolites are imported/exported by dozens of different species31, and may in turn be further associated with additional genera by indirect associations.

Another noteworthy highlight from this network is the consistent positive associations between butyrate, a short-chain-fatty-acid with beneficial effects on intestinal homeostasis, and several genera, including Faecalibacterium, Butyrivibrio (formerly classified as TF0111 genus), Roseburia, Eubacterium_I, Agathobacter, and Lachnospira (Fig. 2b-II; Supplementary Table 4). While the former 5 genera are all known butyrate-producers in the gut32,33,34, Lachnospira does not produce butyrate directly but has an indirect positive effect on other butyrate-producing taxa, upon pectin fermentation35. Interestingly, Flavonifractor is consistently negatively associated with butyrate in our network, albeit known to be a butyrate-producer36. This negative association may reflect an ecological interaction rather than a metabolic one, as Flavonifractor tends to have increased abundance in various host conditions that are also characterized by reduced abundances of major butyrate producers, including disease states, postantibiotic treatments, and during infancy30,36.

Future work on consistent genus-metabolite associations (out of the scope of the current study) could include genomic analyses to infer which associations likely stem from known production/consumption capabilities, which association signals are low due to significant species-level variation that masks genus-level findings, which associations break in disease states, and whether genera associated with multiple metabolites are also key ecological players in microbial interaction networks.

We note that this resource has several obvious limitations. One major limitation is the substantial difference between various metabolomics platforms and the impact of the used platform on the set of chemical classes that can be detected. Short-chain fatty acids, for example, which are known to be important microbial metabolites in the gut, are mostly detectable by gas chromatography-mass spectrometry and may be therefore missing in datasets using other metabolomics methods37. With that in mind, it is important to note that the number of datasets in which a metabolite appears should not be used as an indication of its prevalence. Similarly, differences between methods may result in different scales of metabolite values, and hence a direct comparison of metabolite values between studies should be avoided. Lastly, metabolite identification in untargeted metabolomic platforms may vary in its confidence level, which could in turn imply lower confidence of downstream analyses. To allow users of this resource to better address these issues, we provide detailed information about metabolomics methods and identification confidence levels for each dataset in Supplementary Table 3, and specifically mark metabolites with putative identifications (see Methods)38. On the microbiome side, differences between 16S amplicon sequencing and shotgun sequencing, as well as differences in sequencing depth and library preparations, may all effect the resolution and accuracy of the obtained microbiome profiles. We encourage users of this resource to carefully account for these limitations using appropriate analysis approaches (some of which were described above), and to apply caution when interpreting analysis results. Additional recommendations for how to best utilize the resource are available in the Wiki page. Overall, The Curated Gut Microbiome-Metabolome Data Resource can facilitate a wide and diverse range of integrated microbiome-metabolome analyses, promote the discovery of robust microbe-metabolite links, and allow researchers to easily place newly identified microbe-metabolite findings in the context of other published datasets.

Go here to see the original:

The gut microbiome-metabolome dataset collection: a curated resource for integrative meta-analysis | npj Biofilms and Microbiomes - Nature.com

Read More..

Highly Effective Tips To Improve Your Business Practice – OfficeChai

When it comes to improving your business practice, one of the most important areas that you should concentrate on is business analytics, so before we continue, lets take a closer look at business analytics and what it is all about.

What is business analytics?

Do you ever feel like youre flying blind when it comes to your business? Youre not alone.

Many small business owners feel this way, especially when it comes to making decisions about where to allocate their resources.

Thankfully, there is a solution: business analytics.

Business analytics is the process of unlocking the power of data in order to make better decisions for your business. In this blog post, we will discuss what business analytics is and how you can use it to improve your bottom line.

Business analytics is the process of turning data into insights. It allows you to take a closer look at your business and understand what is working and what isnt. By understanding your data, you can make informed decisions about which areas of your business require attention and how to allocate your resources.

This can help you improve your bottom line and grow your business.

There are many different types of business analytics, but they all have one goal: to help you make better decisions.

The most common type of business analytics is descriptive analytics. Descriptive analytics answers the question: What happened? It helps you understand past events so that you can learn from them.

Another type of business analytics is predictive analytics. Predictive analytics uses data to answer the question: What will happen? It can help you make decisions about the future of your business.

Business analytics can be used to examine many diverse areas of the business. Some common uses include:

How does business analytics work?

Business analytics is all about using data to make better business decisions. By understanding business analytics, businesses can identify trends, track performance and make predictions about the future.

Business analytics involves four key steps:

Lets look at these steps in a little more detail.

Collecting data

Businesses have long been using data to inform their decisions, but the power of data has grown in recent years. With advances in technology, businesses now have more ways to collect and analyze data than ever before.

There are a variety of business analytics methods that businesses can use to make better decisions. Data mining is one method that involves analyzing large data sets to find trends and patterns. Another method is predictive analytics, which uses statistical techniques to predict future events.

Businesses can also use social media analytics to track and analyze social media conversations. This can be used to understand customer sentiment or spot early signs of a product issue.

Cleaning data

There are many different business practices that can be used to clean data, but not all of them are created equally. Some methods are more effective than others, and some may even do more harm than good, so its important to know which business practices to use in order to get the most out of your data.

One business practice that can be used is data cleansing. This is the process of identifying and correcting errors in data. This can be done manually or through automated means. Data cleansing is an important part of maintaining accurate data sets, and it can help improve the quality of your data overall.

Another business practice that can be used to clean data is deduplication, the process of removing duplicate data from a data set. This can also be done manually or through automated means. De-duplication can help improve the quality of your data by ensuring that each piece of data is unique and therefore valid.

Finally, business intelligence can be used to clean data. Business intelligence is the process of analyzing data to extract insights that can be used to improve business decision making. This can be done through a variety of methods, including content analysis.

These are just a few of the business practices that can be used to clean data. Each has its own positives and negatives, so it is vitally important to choose the right one for your business.

Analyzing data

As business analytics has become more prevalent, businesses have started to realize the power of their data. Businesses can use data to improve their practices and make better decisions. There are many different methods that businesses can use to analyze data. Some common methods include:

Each of these methods has its own advantages and disadvantages. Data mining is a good way to find trends in data. Statistical analysis improves the understanding of relationships between different variables. Predictive modeling helps in making predictions about future events, while forecasting is good for planning purposes.

Businesses should choose the method or combination of methods that best suits their needs. No matter what method or combination of methods they choose, business analytics can be a powerful tool for unlocking the power of data.

Reporting analytical data reports

Care should be taken to ensure that the analytical data findings are reported to the relevant department of a business.

For instance, data findings relating to the production of a product would be of little interest to the advertising department, and vice versa.

Presented correctly, data reports can make a massive difference to the effectiveness in all aspects of a business, no matter if the business is a one-man band or a multinational company.

How to get started with business analytics

If you want to get started with business analytics, there are a few key things you need to know.

Firstly, business analytics is the practice of using data to guide business decisions. This means that you need to have access to accurate and up-to-date data to make informed decisions.

Secondly, you need to be able to analyze that data to identify trends and patterns.

Finally, you need to be able to communicate your findings in a way that will help others make better decisions.

The good news is that there are various resources available to help you get started with business analytics. There are plenty of books and articles on the subject, as well as online courses and tutorials.

Business analytics masters degree

A graduate degree in business analytics can give you the skills you need to collect, organize and analyze your data to make better decisions for your company. The advantages of a business analytics degree include:

A graduate degree in business analytics can help you get ahead in your career and give you the skills you need to be successful. If you are interested in pursuing a career in business analytics, consider earning a graduate degree from an accredited online school.

Advantages of studying for a business analytics masters degree online

There are many advantages to pursuing a business analytics masters degree online. One of the key advantages is the ability to study when it is convenient for you. This means that you can fit your studies around other aspects of your business and time spent with family.

Another advantage of studying for your degree online is the flexibility it offers. You can choose when and where you study, which can be particularly beneficial if you live in a remote area, travel frequently or have other commitments that make it difficult to attend on-campus courses.

The range of courses available online is also often wider than what is available on-campus, so you can tailor your studies to your specific interests and career goals. As the courses are accessible from anywhere in the world, youll have access to a global community of fellow students and academics.

It is obviously of paramount importance that you study with a highly reputable course provider such as St Bonaventure University Online, which has been voted as the best regional university value for 2020 by U.S. News & World Report.

Other methods to improve business practice

Setting goals

When it comes to setting goals in business, there are a few things you need to keep in mind. Firstly, you need to make sure that your goals are realistic and achievable. Secondly, you need to ensure that your goals are specific and measurable. Thirdly, you need to set a deadline for your goals. Finally, you need to make sure that your goals are aligned with your companys mission and values.

If you can keep these four things in mind when setting goals in business, youll be on the right track to success. If youre not sure where to start, we have some tips for you below.

Make sure your goals are realistic and achievable.

The first step to setting goals in business is to make sure that theyre realistic and achievable. If you set goals that are too high, youll only end up disappointed, while if you set goals that are too low, you wont be challenging yourself enough. So, find a happy medium. Set goals that are ambitious but still within reach.

Make sure your goals are specific and measurable.

Its not enough to just set a goal such as increase sales. You need to be specific about what you want to achieve and how youre going to measure it. For example, a better goal would be increase sales by 10% over the next quarter. This way, you know exactly what you need to do, and you can track your progress along the way.

Set a deadline for your goals.

If you dont set a deadline for your goals, theyll never get done. So, make sure to give yourself a timeline to work with. This will help you stay on track and motivated to achieve your goals.

Ensure that your goals are aligned with your companys mission and values.

Your goals should always be in line with your companys mission and values. This will help you stay focused on whats important and ensure that your efforts are contributing to the overall success of the company.

By following these tips, youll be well on your way to setting goals in business that are successful. Just remember to be smart, and to always keep your companys mission and values in mind.

Developing systems

Theres no one-size-fits-all answer when it comes to developing systems for business success. However, there are some key tips that can help you create effective systems for your organization.

Keep it simple

The most successful business systems are usually the simplest ones. When developing a system, aim for simplicity and ease of use. This will make it more likely that employees will use the system and that it will be effective.

Automate as much as possible

Automation can help improve efficiency and accuracy in business systems. By automating tasks, you can free up employees time to focus on more important tasks.

Test and refine

Before implementing a business system, its important to test it out. Try it out in a small scale or test environment to see how it works and make sure that it meets your needs. Once youre satisfied with the results, you can roll it out to the rest of your organization.

Be flexible

Flexibility is key when developing business systems. As your organization grows and changes, your system will need to be able to change with it. Be prepared to adjust and refine your system as needed to ensure that it continues to meet your needs.

By following these tips, you can develop systems that will help improve efficiency and productivity in your organization.

Involve people within the business

Firstly, its important to engage your workforce in the process. After all, theyre the ones who will be using the system on a daily basis. You need to involve them in the design and development process so that they feel ownership of the system and are more likely to use it effectively.

Secondly, you need to make sure that the system is designed to meet the specific needs of your business. Theres no point in developing a system that doesnt fit with your companys culture or business goals.

Finally, you need to ensure that the system is constantly evolving. Technology changes rapidly, and your business needs to change with it. Regularly review and update your system so that it remains effective over time.

Conclusion

As you can see, there are lots of methods that can be used when it comes to improving your business practice.

Perhaps the main thing to bear in mind is that improving your business is always an ongoing process.

Admittedly, having a degree in the subject of business analytics is a great start, but any enterprise that thinks that they cannot improve their business practice in any way will be doomed to fail in the long run.

Constant improvement is the foundation of any successful business, so bear that in mind whether you are a business owner or an employee.

Read more here:

Highly Effective Tips To Improve Your Business Practice - OfficeChai

Read More..

5 steps to develop a dashboard to better manage your operations – MedCity News

To make informed choices, the care-at-home industry needs to base its decisions on evidence. Business intelligence has traditionally taken the form of quarterly or yearly reports that monitor a defined set of key performance indicators (KPIs), but todays software-backed tools work continuously and at lightning speed. The mountains of data that organizations produce using their electronic medical record (EMR), combined with available market data, will help reveal valuable patterns and trends.

Building an analytics dashboard

How do organizations optimize and scale business intelligence? Here are five basic steps to consider when developing dashboards to assess your operational, financial and quality components within the care at home industry.

1. Define: The first step is to identify the end goal of a report. Keep the goal broad enough that it will allow you to measure a variety of metrics, but narrow enough to prevent overwhelming data.

2. Assign team: Assign a team to own measuring metrics. Depending on your organization size, you may have additional departments, such as education and training, intake and budgeting. Define champions within each department (these can be subject matter experts) to drive the goal, as well as the metrics within.

3. Define metrics: Remember, garbage in is garbage out. Metrics that 1) drive success and value, 2) are easy to understand and 3) lead operators to implement corrective action concurrently will stand the test of reliable data.

4. Map connections: You know the goal, who needs the information and what they should measure. Now its time to find where that information lives. Determine the data source for each metric, being as specific as possible. Examples:

5. Compare data: Youve done all the legwork, now its time to build your dashboard. Determine time periods for data comparisons: Week over week, month over month, etc. Some data may not have enough information to compare day over day. Data can be filtered multiple ways for comparisons. For example, break it down by payer source or branch to gain additional insights. It is important that a dashboard allows for multiple comparisons points.

Compiling the results

As you blend data from various connectors, be sure to follow data cleanliness standards so your team can trust what theyre seeing. The end report should be visual and easy to read and have been vetted through quality improvement (QI) before presenting to a larger group.

Look for inconsistencies. If there are discrepancies, your team needs to research, validate and correct the metrics (the single source of truth), which will evolve over time.

Management styles: Reports vs. exception

Organizations need to be cautious of information overload (the excess of information available to a person aiming to complete a task or make a choice), typically resulting in a poor decision being made or none at all. This analysis paralysis is common in the fast-paced world of healthcare operations.Leaders are inundated with metrics from multiple sources that are not always actionable or concurrent. Too often this leads to no action and poor outcomes.

To reduce the risk of analysis paralysis, organizations should focus on managing by reports and by exception in three key areas: operations, finance and quality.

Management by reports communicates business results, issues and risk and is critical for directing a business. Including key performance metrics will provide density and textual information.

Management by exception is a style that focuses on identifying and handling cases that deviate from the norm. This enables management to practice by exception, narrowing focus to problem areas and creating concurrent actionable items to improve outcomes.

Putting these management styles to use

Both management by reports and by exception factors in two types of retrospective analytics found in business intelligence:

It is through proactive analytics that the care at home industry can improve employee and patient engagement, relationship management and clinical care. The two forms of proactive analytics are:

These insights can help a company choose a course of action in a matter of minutes.

Only once you understand the behaviors behind essential metrics can your organization move performance toward excellence.

Photo: Nuthawut Somsuk, Getty Images

Excerpt from:

5 steps to develop a dashboard to better manage your operations - MedCity News

Read More..

The first crop of space mining companies didn’t work out, but a new generation is trying again – CNBC

Just a couple of years ago, it seemed that space mining was inevitable. Analysts, tech visionaries and even renowned astrophysicist Neil deGrasse Tyson predicted that space mining was going to be big business.

Space mining companies like Planetary Resources and Deep Space Industries, backed by the likes of Google's Larry Page and Eric Schmidt, cropped up to take advantage of the predicted payoff.

Fast forward to 2022, and both Planetary Resources and Deep Space Industries have been acquired by companies that have nothing to do with space mining. Humanity has yet to commercially mine even a single asteroid. So what's taking so long?

Space mining is a long-term undertaking and one that investors do not necessarily have the patience to support.

"If we had to develop a full-scale asteroid mining vehicle today, we would need a few hundred million dollars to do that using commercial processes. It would be difficult to convince the investment community that that's the right thing to do," says Joel Sercel, president and CEO of TransAstra Corporation.

"In today's economics and in the economics of the near future, the next few years, it makes no sense to go after precious metals in asteroids. And the reason is the cost of getting to and from the asteroids is so high that it vastly outstrips the value of anything that you'd harness from the asteroids," Sercel says.

This has not dissuaded Sercel from trying to mine the cosmos. TransAstra will initially focus on mining asteroids for water to make rocket propellant, but would like to eventually mine "everything on the periodic table." But Sercel says such a mission is still a ways off.

"In terms of the timeline for mining asteroids, for us, the biggest issue is funding. So it depends on how fast we can scale the business into these other ventures and then get practical engineering experience operating systems that have all the components of an asteroid mining system. But we could be launching an asteroid mission in the 5 to 7-year time frame."

Sercel hopes these other ventures keep it afloat until it develops its asteroid mining business. The idea is to use the tech that will eventually be incorporated into TransAstra's astroid mining missions to satisfy already existing market needs, such as using space tugs to deliver satellites to their exact orbits and using satellites to aid in traffic management as space gets increasingly more crowded.

AstroForge is another company that believes space mining will become a reality. Founded in 2022 by a former SpaceX engineer and a former Virgin Galactic engineer, AstroForge still believes there is money to be made in mining asteroids for precious metals.

"On Earth we have a limited amount of rare earth elements, specifically the platinum group metals. These are industrial metals that are used in everyday things your cell phone, cancer, drugs, catalytic converters, and we're running out of them. And the only way to access more of these is to go off world," says AstroForge Co-Founder and CEO Matt Gialich.

AstroForge plans to mine and refine these metals in space and then bring them back to earth to sell. To keep costs down, AstroForge will attach its refining payload to off-the shelf satellites and launch those satellites on SpaceX rockets.

"There's quite a few companies that make what is referred to as a satellite bus. This is what you would typically think of as a satellite, the kind of box with solar panels on it, a propulsion system being connected to it. So for us, we didn't want to reinvent the wheel there," Gialich says. "The previous people before us, Planetary Resources and DSI [Deep Space Industries], they had to buy entire vehicles. They had to build much, much larger and much more expensive satellites, which required a huge injection of capital. And I think that was the ultimate downfall of both of those companies."

The biggest challenge, AstroForge says, is deciding which asteroids to target for mining. Prior to conducting their own missions, all early-stage mining companies have to go on is existing observation data from researchers and a hope that the asteroids they have selected contain the minerals they seek.

"The technology piece you can control, the operations pieces you can control, but you can't control what the asteroid is until you get there," says Jose Acain, AstroForge Co-Founder and CTO.

To find out more about the challenges facing space mining companies and their plans to make space mining a real business watch the video.

Go here to read the rest:

The first crop of space mining companies didn't work out, but a new generation is trying again - CNBC

Read More..

A glossary of commonly used breast cancer terminology – Meadville Tribune

Axillary nodes The lymph nodes under the arm.

Benign Not cancer.

Bilateral Affecting or about both the right and left sides of body. For example, a bilateral mastectomy is removal of both breasts.

Biobank (tissue repository) A large collection of tissue samples and medical data that is used for research studies.

Bioinformatics The field of endeavor that relates to the collection, organization and analysis of large amounts of biological data using networks of computers and databases.

Biopsy Removal of tissue to be looked at under a microscope.

BRCA1/BRCA2 Genes (breast cancer genes) Genes that help limit cell growth. A mutation in one of these genes increases a persons risk of breast, ovarian and certain other cancers.

Breast cancer An uncontrolled growth of abnormal breast cells.

Breast density A measure used to describe the relative amounts of fat and tissue in the breasts as seen on a mammogram.

Calcifications Deposits of calcium in the breast that appear as bright, white spots on a mammogram.

Cell The basic unit of any living organism.

Chemotherapy A drug or combination of drugs that kills cancer cells in various ways.

Clinical breast examination A physical exam done by a health care provider to check the look and feel of the breasts and underarm for any changes or abnormalities, such as lumps.

Clinical trials Research studies that test the benefits of possible new ways to detect, diagnose, treat or prevent disease. People volunteer to take part in these studies.

Core needle biopsy A needle biopsy that uses a hollow needle to remove samples of tissue from an abnormal area in the breast.

Ct scan (computerized tomography scan) A series of pictures created by a computer linked to an X-ray machine.

The scan gives detailed internal images of the body.

Cyst A fluid-filled sac.

Data mining The ability to query very large databases in order to satisfy a hypothesis (top-down data mining); or to interrogate a database in order to generate new hypotheses based on rigorous statistical correlations (bottom-up data mining).

DNA (deoxyribonucleic acid) The information contained in a gene.

DNA sequencing The technique in which the specific sequence of bases forming a particular DNA region is deciphered.

Expression (gene or protein) A measure of the presence, amount, and time-course of one or more gene products in a particular cell or tissue. Expression studies are typically performed at the RNA (mRNA) or protein level in order to determine the number, type and level of genes that may be up-regulated or down-regulated during a cellular process, in response to an external stimulus, or in sickness or disease.

Family history A record of the current and past health conditions of a persons blood-related family members that may help show a pattern of certain diseases within a family.

Genes The part of a cell that contains DNA. The DNA information in a persons genes is inherited from both sides of a persons family.

Gene expression Process in which a gene gets turned on in a cell to make RNA and proteins.

Genetic testing Analyzing DNA to look for a gene mutation that may show an increased risk for developing a specific disease.

Genome The total genetic information of an organism.

Genomic testing Analyzing DNA to check for gene mutations of a cancer tumor.

Genomics The study of genes and their functions.

Immunotherapy Therapies that use the immune system to fight cancer. These therapies target something specific to the biology of the cancer cell, as opposed to chemotherapy, which attacks all rapidly dividing cells.

Implant An envelope containing silicone, saline or both, that is used to restore the breast form after a mastectomy.

Informatics The science of information; the collection, classification, storage, retrieval, and dissemination of recorded knowledge treated both as a pure and as an applied science.

Invasive breast cancer Cancer that has spread from the original location into the surrounding breast tissue and possibly into the lymph nodes and other parts of the body.

Lesion Area of abnormal tissue.

Linear accelerator The device used during radiation therapy to direct X-rays into the body.

Lumpectomy (breast conserving surgery) Surgery that removes part of the breast the area containing and closely surrounding the tumor.

Lymph nodes Small groups of immune cells that act as filters for the lymphatic system. Clusters of lymph nodes are found in the underarms, groin, neck, chest and abdomen.

Lymphedema Swelling due to poor draining of lymph fluid that can occur after surgery to remove lymph nodes or after radiation therapy to the area.

Malignant Cancerous.

Mammogram An X-ray image of the breast.

Mastectomy Surgical removal of the breast. The exact procedure depends on the diagnosis.

Medical oncologist A physician specializing in the treatment of cancer using chemotherapy, hormone therapy and targeted therapy.

Metastasize When cancer cells spread to other organs through the lymphatic and/or circulatory system.

MRI (magnetic resonance imaging) An imaging technique that uses a magnet linked to a computer to make detailed pictures of organs or soft tissues in the body.

Mutation Any change in the DNA of a cell. Gene mutations can be harmful, beneficial or have no effect.

Nipple-sparing mastectomy A breast reconstruction procedure that removes the tumor and margins as well as the fat and other tissue in the breast, but leaves the nipple and areola intact.

PET (positron emission tomography) A procedure where a short-term radioactive sugar is given through an IV so that a scanner can show which parts of the body are consuming more sugar. Cancer cells tend to consume more sugar than normal cells do. PET is sometimes used as part of breast cancer diagnosis or treatment, but is not used for breast cancer screening.

Protein Any of various naturally occurring extremely complex substances that consist of amino-acid residues joined by peptide bonds, contain the elements carbon, hydrogen, nitrogen, oxygen, usually sulfur and occasionally other elements.

Proteomics The cataloging of all the expressed proteins in a particular cell or tissue type, obtained by identifying the proteins from cell extracts.

Prophylactic mastectomy Preventive surgery where one or both breasts are removed in order to prevent breast cancer.

Radiation oncologist A physician specializing in the treatment of cancer using targeted, high energy X-rays.

Radiation Therapy Treatment given by a radiation oncologist that uses targeted, high energy X-rays to kill cancer cells.

Radiologist A physician who reads and interprets X-rays, mammograms and other scans related to diagnosis or follow-up.

Radiologists also perform needle biopsies and wire localization procedures.

RNA (ribonucleic acid) A molecule made by cells containing genetic information that has been copied from DNA. RNA performs functions related to making proteins.

Sentinel node biopsy The surgical removal and testing of the sentinel nodes the first axillary nodes in the underarm area filtering lymph fluid from the tumor site to see if the node contains cancer cells.

Stage of cancer A way to indicate the extent of the cancer within the body. The most widely used staging method for breast cancer is the TNM system, which uses Tumor size, lymph Node status and the absence or presence of Metastases to classify breast cancers.

Targeted therapy Drug therapies designed to attack specific molecular agents or pathways involved in the development of cancer. Herceptin is an example of a targeted therapy used to treat breast cancer Tomosynthesis (3D Mammography, Digital Tomosynthesis) A tool that uses a digital mammography machine to take multiple two dimensional X-ray images of the breast. Computer software combines the multiple 2D images into a three dimensional image.

Tumor An abnormal growth or mass of tissue that may be benign (not cancerous) or malignant (cancerous).

Ultrasound Diagnostic test that uses sound waves to make images of tissues and organs. Tissues of different densities reflect sound waves differently.

Sources: Susan G. Komen; Federal University of Rio Grande do Sul, Brazil.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

Read the original post:

A glossary of commonly used breast cancer terminology - Meadville Tribune

Read More..

Connected intelligence helps SA manufacturers transition to Industry 4.0 – IT-Online

Agility is critical for South African manufacturers looking to modernise their environments. They need to embrace the concept of Industry 4.0 to leverage cloud-based technology and cyber-physical systems to operate the smart factory required in todays digital world.

By Morn de Villiers: integration architect and project manager at TechSoft International

An intelligent manufacturing solution must be considered if a business is to bridge the gap between existing legacy solutions and the connected ones needed for the cloud. This will help local operators gain supply chain efficiencies and compete in the global marketplace.

When a business can make intelligent decisions, it can optimally allocate its people and resources to minimise machine and equipment downtime. Process automation becomes essential in this regard.

When a manufacturer uses the data generated through this intervention and power intelligent automation, it can reduce manual processes, increase productivity, refocus its workers on more value-added tasks, and enable better decision-making across the organisational footprint.

Data integration

Manufacturers collect, store, and use data across various machines, systems, and data repositories. This data needs to be unified to optimise efficiency to provide business and technology leaders with complete access. Protocols are numerous, which presents a challenge in connecting the data across operations. Connecting the various data stores takes cloud-based intelligence, data mining, and analytics.

A connected intelligence platform that integrates data across processes, equipment, and Industrial Internet of Things devices becomes the cornerstone of the shift toward Industry 4.0. Furthermore, this platform can intelligently unify data for greater access and control and confidently predict the future to help reduce costs, improve operational efficiencies, and increase profitability.

South African manufacturers understand all too well the need for consistent production processes. Intelligent automation does provide for this. Quality control (QC) is used to identify defects or flawed products, but this takes up valuable time and resources. It is, therefore, better to have consistent production that ensures each product is flawless.

Reducing or eliminating inconsistencies saves time and resources in QC. It also lowers defect rates on products delivered to buyers. Artificial intelligence (AI) models empower manufacturers to combine historical and real-time supply chain data to find quality issues early. The AI learns from automated root-cause analysis and other processes to dynamically improve quality consistency.

Injecting resilience

Supply chain optimisation is vital if a manufacturer is to be competitive in modern distribution channels. Buyers throughout the distribution channel rely on on-time delivery of products. Any delays or bottlenecks in production and distribution provide competitors with a significant advantage in filling orders.

Industry 4.0 and automated intelligence enable proactive responses to supply chain changes. Instead of manually recognising demand changes or problems, the data reveals inventory insights and allows the business to optimise transportation and logistics as required.

Locally, manufacturers must contend with significant industry regulations impacting production processes and products. And while South Africa is not unique in this regard, it does introduce a new layer of complexity into the process. Fortunately, Industry 4.0 automation enables greater efficiency and accuracy in meeting compliance by reducing opportunities for human error, improving audit and tracking information, and providing analytics that helps identify potential compliance issues before they arise.

Driving revenue and profit

Companies will see optimised revenue and profit by adopting automated processes and benefitting from greater accuracy resulting from manufacturing intelligence. They can maximise resource utilisation to deliver products on time while keeping costs minimum. Automation also enables agility as manufacturers scale to accommodate new customers or products being brought to market.

As a result of the events over the past two years, Industry 4.0 is foundational to the manufacturing ecosystems success. Automation brings benefits such as integrated data insight, process optimisation, supply chain resilience, and compliance with industry regulations that cannot be ignored.

Getting a connected intelligence platform in place to provide manufacturing intelligence for the modern smart factory is no longer a luxury but a business necessity for local companies.

Related

Go here to see the original:

Connected intelligence helps SA manufacturers transition to Industry 4.0 - IT-Online

Read More..

Candy for Thought: These are the top 3 Halloween candies in Washington this year – Curiocity

With Halloween just a few weeks away youre probably seeing a lot of candy lining your local stores aisles. And with so many options these days it can be hard to choose just which candy to grab for your neighborhood trick-or-treaters. However, a brand new map shows which candy Americans favor by each state, lets see which candy Washington loves most.

Candystore.com used its annual data mining to determine the top 3 most popular Halloween candies in each state. Lets just say as we return to full-blown Halloween, the results are somewhat surprising. That being said, Americans are going big this year with theNational Retail Federation, predicting Halloween candy sales of around $3.1 Billion, an all-time high.

Recent Posts:6 of the best places to buy Halloween costumes in & around SeattleHere are 6 Seattle-themed Halloween costume ideas

The top three favorite candies in Washington in order this year are Tootsie Pops, Salt Water Taffy, and M&Ms. Tootsie Pops? Seriously? Its a big switch up from last years, which according to a different study was Nerds. We have to say Nerds still seem a little more appropriate but hey well give Tootsie Pops a go this year.

If youre curious our neighbors down south in Oregon are all about M&Ms and our neighbors to the east in Idaho are snickering their way through spooky season with Snickers.

With that, Happy Halloween!

With a curated slate of what matters in your city, Curiocity presents you with the most relevant local food, experiences, news, deals, and adventures. We help you get the most out of your city and focus on the easy-to-miss details so that youre always in the know.

Follow this link:

Candy for Thought: These are the top 3 Halloween candies in Washington this year - Curiocity

Read More..

EXCLUSIVE: CDC Won’t Release Review of Post-Vaccination Heart Inflammation – The Epoch Times

The U.S. Centers for Disease Control and Prevention (CDC) will not release its review of post-COVID-19-vaccination heart inflammation.

The CDC has been performing abstractions on reports of post-vaccination myocarditis, a form of heart inflammation, submitted to theVaccine Adverse Event Reporting System.

But the agency is saying that federal law prevents it from releasing the results.

The abstractions are considered medical records which are withheld in full from disclosure, the CDC told The Epoch Times in a recent letter, responding to a Freedom of Information Act request.

One of the exemptions in the act says that agencies can withhold materials that are specifically exempted from disclosure by statute, if that statute(i) requires that the matters be withheld from the public in such a manner as to leave no discretion on the issue; or (ii) establishes particular criteria for withholding or refers to particular types of matters to be withheld; and (B) if enacted after the date of enactment of the OPEN FOIA Act of 2009, specifically cites to this paragraph.

The CDC pointed to the Public Health Service Act, which was enacted in 1944, and says that vaccine injury reports and other information that may identify a person shall not be made available to any person except the person who received the vaccine or a legal representative for that person.

The information sought is available through the CDC websitewithout details that would identify patients, the agency also said.

The CDC said that it does not have a formal definition of abstraction but that it means the process of reviewing medical records, including autopsy reports and death certificates, and recording data in a database. Please note that this definition means that any abstracted data, because they originate from medical records, is also considered medical records, a CDC records officer told The Epoch Times in an email.

Refusing to release the data raises concerns about transparency, according to Barbara Loe Fisher, co-founder and president of the National Vaccine Information Center.

The stubborn refusal of officials heading up federal health agencies responsible for protecting the public health to come clean with Americans about what they know about COVID vaccine risks is stunning, Fisher told The Epoch Times in an email.

Fisher noted that the CDC has funded electronic medical record systems that collect personal health information and that the agency shares the data with a number of third parties, such as contractors and researchers.

Yet, CDC officials are claiming they cannot release de-identified abstraction information curated from the medical records of individuals, who have suffered myocarditis or died after COVID shots? This looks and feels like a coverup of the true risks of COVID vaccines, Fisher said.

Fisher called for a congressional probe into what she described as the disturbing lack of transparency on the part of federal agency officials, who granted COVID vaccine manufacturers an Emergency Use Authorization (EUA) to widely distribute the vaccines in December 2020 and have recommended and aggressively promoted the vaccines for mandated use ever since.

In response to a separate Freedom of Information Act request, the CDC initially said that it did not perform any abstractions or produce any reports on post-vaccination myocarditis. That request was for reports betweenApril 2, 2021, and Oct. 2, 2021.

The agency alsofalsely said that a link between myocarditis and the messenger RNA COVID-19 vaccines was not known during that time.

A possible link between those vaccines, made by Pfizer and Moderna, became known in early 2021. Many experts now acknowledge the link is likely or definitely causal.

The CDC later issued a correction on the false claim, as well as the claim that the agency started performing a type of data mining on VAERS data as early as February 2021.

The CDC said in its correction that myocarditis abstractions began being performed in May 2021.

Notified that its response was false and asked to do a fresh search, the records office did not respond.

Appeals have been lodged in that case and after the more recent response withholding the records.

Dr. Rochelle Walensky, the CDCs director, said in a press conference in April 2021 that the agency had not detected a link between the vaccines and myocarditis. The basis for that statement remains unclear.

The refusal to provide the myocarditis abstractions is part of a pattern with the CDCand its partner, the Food and Drug Administration (FDA).

The CDC still hasnt released the results of the data mining, to The Epoch Times, Sen. Ron Johnson (R-Wis.), or a nonprofit called Childrens Health Defense. The agency also declined to provide results from a different monitoring system, V-safe, to a nonprofit called Informed Consent Action Network, which then sued the agency and just recently received the first tranche of data.

The FDA, meanwhile, has refused to release the results of a different type of analysis on the VAERS data, claiming it cannot separate the results from protected internal communications. The agency is also withholding autopsies conducted on people who died after getting COVID-19 vaccines, pointing to exceptions laid out in the Freedom of Information Act.

Along with Johnson, several other lawmakers are pressing at least one of the agencies to release the data, asserting that not doing so is illegal.

Follow

Zachary Stieber covers U.S. and world news for The Epoch Times. He is based in Maryland.

View original post here:

EXCLUSIVE: CDC Won't Release Review of Post-Vaccination Heart Inflammation - The Epoch Times

Read More..

Crowdfunding for medical treatment: Bombay HC asks govt if children can be displayed in ads by private firms – The Indian Express

The Bombay High Court recently sought to know from the Maharashtra government and Mumbai Police to inform as to whether an online crowdfunding for medical treatments such as cancer and other rare diseases can be done by a private organisation or a company and if the same is permissible, which is the monitoring authority for the same.

The bench sought states response while hearing plea by Impact Guru Technology Ventures, a crowdfunding platform, challenging show-cause notice issued to it by Police under the the Juvenile Justice (Care and Protection of Children) Act, 2000 for displaying child in wrong perspective on its social media advertisements and sought interim relief as it apprehended FIR.

A division bench of Justice Prasanna B Varale and Justice Nitin R Borkar on October 6 was hearing plea by the private firm challenging September 7 show-cause notice issued by the state Special Inspector of General Police, Prevention of Crime Against Women and Children asking the petitioner why crime under section 76 of the JJ Act should not be registered against the firm.

As per Section 76 of JJ Act, whoever employs or uses any child for the purpose of begging or causes any child to beg shall be punishable with imprisonment for a term which may extend to five years and shall also be liable to fine of one lakh rupees.

Advocate Niteen Pradhan for the petitioner submitted that it is a private limited company with a primary objective to manage a technology platform, which enables patients to seek funds/ donations for medical treatment such as cancer, organ transplant and other rare diseases; from friends, relatives and public at large through online fundraising.

He submitted that as per the notice, advertisements prepared by petitioner company, which were circulated through various mediums including You-Tube, Facebook etc. are displaying the child in the wrong perspective.The police had said the advertisements and money collected fall in the category of begging under JJ Act and therefore the firm was indulging in activities inconsistent with the 2000 law.

Pradhan submitted that petitioners activity is permissible under the National Policy for Rare Diseases, 2021, as there are government portals for crowd funding and therefore, the show-cause notice was misconceived and same be set aside.

He added that petitioner apprehended coercive action through an FIR being initiated by the Police and sought an interim order to protect the company.

The Court noted that there were no avertments made by petitioner to show that it was not retaining any amount out of the funds or donation received and if it was retaining some percentage of amount, it has not shown how much was the same.

The bench noted that Clause 10 of the 2021 policy provides the government to create an alternate funding mechanism through a digital platform for voluntary individuals and corporate donors to contribute to the treatment cost of patients of rare diseases, as it would be difficult for government to fully finance high cost treatment for rape diseases.

The gap can however be filled by creating a digital platform for bringing together notified hospitals where such patients are receiving treatment or coming for treatment, on the other hand, and prospective individual or corporate donors willing to support treatment of such patients, the policy states.

The Court perused the policy and observed that it was unable to find any material permitting private organisations or company to display such information about a child on a public platform

The bench then asked the state government and Mumbai Police to file reply to the petition on aspects of which Act or Regulation governs the crowd funding and can the same be done by private companies and if it is permissible, which will be an authority monitoring the same.

After Public Prosecutor Aruna Pai for state on instructions from the concerned police officer submitted that no action/steps will be taken against the petitioner pursuant to the notice till the next hearing, the bench posted the matter to October 19.

Here is the original post:
Crowdfunding for medical treatment: Bombay HC asks govt if children can be displayed in ads by private firms - The Indian Express

Read More..

Upgrading your computer to quantum – techexplorist.com

Computers that can use quantum mechanics properties solve problems faster than current technology. This is interesting, but they must overcome a massive disadvantage in doing so.

Niobium nitride, a superconducting substance, can be added to a nitride-semiconductor substrate to form a flat, crystalline layer, as demonstrated by Japanese researchers, who may have provided the solution. This method might be simple to produce quantum qubits that can be used with regular computing devices.

A team of researchers at the Institute of Industrial Science at The University of Tokyo has shown how thin films of niobium nitride (NbNx) can be grown directly on top of an aluminum nitride (AlN) layer. Niobium nitride can become superconducting at temperatures colder than 16 degrees above absolute zero.

When placed in a device known as a Josephson junction, it can be utilized to create a superconducting qubit. The researchers examined the effect of temperature on the crystal structures and electrical characteristics of NbNx thin films produced on AlN template substrates. They demonstrated that the two materials atom spacing was compatible enough to result in flat layers.

First and the corresponding author Atsushi Kobayashi said, We found that because of the small lattice mismatch between aluminum nitride and niobium nitride, a highly crystalline layer could grow at the interface.

The crystallinity of the NbNx was characterized with X-ray diffraction, and the surface topology was captured using atomic force microscopy. In addition, the chemical composition was checked using X-ray photoelectron spectroscopy. The team showed how the arrangement of atoms, nitrogen content, and electrical conductivity all depended on the growth conditions, especially the temperature.

The structural similarity between the two materials facilitates the integration of superconductors into semiconductor optoelectronic devices.

Moreover, the sharply defined interface between the AlN substrate, which has a wide bandgap, and NbNx, which is a superconductor, is essential for future quantum devices, such as Josephson junctions. Superconducting layers that are only a few nanometers thick and have high crystallinity can be used as detectors of single photons or electrons.

Journal Reference:

Read this article:
Upgrading your computer to quantum - techexplorist.com

Read More..